B. Riley analyst Yuan Zhi initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $1.20 price target. The company’s Pb-212 approach is a promising targeted alpha therapy platform that is differentiated from others, such as Fusion Pharmaceutical’s (FUSN) Ac-225-based platform, because it offers a unique theragnostic pair and short half-life, the analyst tells investors in a research note. The firm believes Perspective is well positioned “to break out of the biotech pack and is worth investors’ attention.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CATX:
- Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
- Perspective Therapeutics 132.08M share Spot Secondary priced at $0.37
- Perspective Therapeutics prices 132.08M shares at 37c in public offering
- Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
- Perspective Therapeutics Announces Proposed Public Offering
